TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19327776

Group type: EXPERIMENTAL
Intervention: On-treatment apolipoproteins A1 and B
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intensive lipid-lowering treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual-dose simvastatin
Number of subjects: 0
Study: 17608061

Group type: EXPERIMENTAL
Intervention: Auricular acupuncture with indwelling fixed needles (points lung, shenmen, forehead and hip)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Sham procedure (4 non-acupuncture points on the helix)
Number of subjects: 64
Study: 15330021

Group type: EXPERIMENTAL
Intervention: Computer-assisted total knee replacement
Number of subjects: 6

Group type: COMPARATOR
Intervention: Conventional jig-assisted total knee replacement
Number of subjects: 6
Study: 11495621

Group type: COMPARATOR
Intervention: Studies published during 1966-1990
Number of subjects: 593

Group type: EXPERIMENTAL
Intervention: Studies published during 1991-2000
Number of subjects: 593
Study: 9432318

Group type: EXPERIMENTAL
Intervention: Clarithromycin 500 mg tid and omeprazole 40 mg/day for 2 weeks, followed by omeprazole (20 or 40 mg daily) for 2 additional weeks.
Number of subjects: 0
Study: 8496462

Group type: EXPERIMENTAL
Intervention: Intralesional interferon-alpha (1 million U, injected three times weekly for 6 weeks)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Sterile water (placebo control)
Number of subjects: 14
Study: 3103950

Group type: EXPERIMENTAL
Intervention: recombinant tissue‐type plasminogen activator (rt‐PA) (n = 77)
Number of subjects: 290

Group type: COMPARATOR
Intervention: streptokinase (SK) (n = 68)
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Both rt‐PA and SK
Number of subjects: 290
Study: 28872700

Group type: EXPERIMENTAL
Intervention: Colonoscopy followed by esophagogastroduodenoscopy (EGD)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Esophagogastroduodenoscopy (EGD) followed by colonoscopy
Number of subjects: 120
Study: 27815148

Group type: EXPERIMENTAL
Intervention: Conditional cash transfer (monthly cash transfer conditional on school attendance ≥80% of school days per month)
Number of subjects: 2537

Group type: COMPARATOR
Intervention: No cash transfer (control group)
Number of subjects: 2537

Group type: EXPERIMENTAL
Intervention: Both groups (overall comparison)
Number of subjects: 2537
Study: 24096730

Group type: EXPERIMENTAL
Intervention: Handwashing with soap and water plus hand sanitizer (Experimental Group)
Number of subjects: 1341

Group type: COMPARATOR
Intervention: Usual handwashing procedure (Control Group)
Number of subjects: 1341
Study: 23179896

Group type: EXPERIMENTAL
Intervention: Olmesartan 10 mg (up-titrated to 20 mg or 40 mg if needed)
Number of subjects: 1453

Group type: COMPARATOR
Intervention: Ramipril 2.5 mg (up-titrated to 5 mg or 10 mg if needed)
Number of subjects: 1453

Group type: EXPERIMENTAL
Intervention: Olmesartan (in patients with valid ambulatory BP recordings and metabolic syndrome)
Number of subjects: 1453

Group type: COMPARATOR
Intervention: Ramipril (in patients with valid ambulatory BP recordings and metabolic syndrome)
Number of subjects: 1453

Group type: EXPERIMENTAL
Intervention: Olmesartan
Number of subjects: 1453

Group type: COMPARATOR
Intervention: Ramipril
Number of subjects: 1453
Study: 20557330

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 300

Group type: COMPARATOR
Intervention: Glyburide
Number of subjects: 300
Study: 19011368

Group type: EXPERIMENTAL
Intervention: Interactive program
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Didactic intervention
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 120
Study: 16183007

Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention to improve cancer pain management
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Pain characteristics (severity, duration, meaning of pain, perceived availability and efficacy of pain relief)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 157
Study: 14974812

Group type: EXPERIMENTAL
Intervention: Bovine porous bone mineral (BPBM) with enamel matrix proteins (EMP)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Simplified papilla preservation (SPP) flap with enamel matrix proteins (EMP)
Number of subjects: 60
Study: 14670700

Group type: EXPERIMENTAL
Intervention: Contours displayed in isolation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Contours displayed within face-like contexts (cartoon faces)
Number of subjects: 0
Study: 9884178

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 500

Group type: COMPARATOR
Intervention: Control conditions (not specified)
Number of subjects: 500
Study: 7617626

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus electrophoresis and UV blood irradiation (group 1)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Chemotherapy alone (group 2)
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Combined therapy (group 1)
Number of subjects: 222
Study: 2651492

Group type: EXPERIMENTAL
Intervention: PPA 75 mg sustained release
Number of subjects: 837

Group type: EXPERIMENTAL
Intervention: PPA 25 mg
Number of subjects: 837

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 837
Study: 63128

Group type: EXPERIMENTAL
Intervention: Combined audio-video channel
Number of subjects: 20

Group type: COMPARATOR
Intervention: Audio channel
Number of subjects: 20

Group type: COMPARATOR
Intervention: Video channel
Number of subjects: 20

Group type: COMPARATOR
Intervention: Audio followed by video (version b)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Video followed by audio (version a)
Number of subjects: 20
Study: 31757429

Group type: EXPERIMENTAL
Intervention: Oxytocin administration
Number of subjects: 160
Study: 30547316

Group type: EXPERIMENTAL
Intervention: F14512 at dose level 10 mg/m2/day
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: F14512 at dose level 5 mg/m2/day
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Overall patient outcomes
Number of subjects: 11
Study: 28855568

Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (rGH)
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study: 25851025

Group type: EXPERIMENTAL
Intervention: Traditional Iranian Pharmacy formulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Marketed formulation
Number of subjects: 0
Study: 23697964

Group type: EXPERIMENTAL
Intervention: Renal denervation (RDN)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (non-RDN)
Number of subjects: 50
Study: 21462059

Group type: EXPERIMENTAL
Intervention: Problem Solving Therapy (PST), 1 to 8 sessions, 45 minutes each with a social worker
Number of subjects: 107
Study: 19686597

Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg every other week
Number of subjects: 315

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 315
Study: 16787129

Group type: EXPERIMENTAL
Intervention: Health behavior change program
Number of subjects: 0
Study: 15303109

Group type: EXPERIMENTAL
Intervention: High-protein diet (HP)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Medium-protein diet (MP)
Number of subjects: 50
Study: 11045895

Group type: EXPERIMENTAL
Intervention: Dextromethorphan 30 mg
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 9308139

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO2) delivered inside the Gamow bag with a demand valve regulator mask at a Po2 of 1.58 atm abs for 40 min.
Number of subjects: 12

Group type: COMPARATOR
Intervention: Normobaric oxygen (NBO2) using a non-rebreather mask at a rate of 15 liter/min outside the Gamow bag for 40 min.
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both HBO2 and NBO2 were tested for COHb elimination kinetics.
Number of subjects: 12
Study: 8346588

Group type: EXPERIMENTAL
Intervention: 50 IU Salcatonin
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: 100 IU Salcatonin
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: 200 IU Salcatonin
Number of subjects: 208

Group type: COMPARATOR
Intervention: Calcium (placebo)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Salcatonin (any dose)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Calcium alone
Number of subjects: 208
Study: 29718143

Group type: EXPERIMENTAL
Intervention: Covering empirical antibiotic treatment (EAT)
Number of subjects: 406

Group type: COMPARATOR
Intervention: Noncovering empirical antibiotic treatment (EAT)
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Covering EAT
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Colistin monotherapy and colistin-carbapenem combination EAT
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Covering antibiotics in propensity score-matched cohort (n = 338)
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: 14-day mortality analysis
Number of subjects: 406
Study: 26999280

Group type: EXPERIMENTAL
Intervention: Exploratory Factor Analysis (EFA)
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Confirmatory Factor Analysis (CFA)
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Higher-order psychopathology construct
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Longitudinal assessment
Number of subjects: 270
Study: 24344211

Group type: EXPERIMENTAL
Intervention: Interferon alfa‐2b (IFN‐α‐2b) 20 MIU/m(2) intravenously (IV) daily 5 days per week for 4 weeks (arm A)
Number of subjects: 194

Group type: COMPARATOR
Intervention: Interferon alfa‐2b (IFN‐α‐2b) 20 MIU/m(2) intravenously (IV) daily 5 days per week for 4 weeks followed by IFN‐α‐2b 10 MIU/m(2) administered subcutaneously three times per week for 48 weeks (arm B)
Number of subjects: 194
Study: 22987303

Group type: EXPERIMENTAL
Intervention: Coffee (100 ml three times daily)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Water (100 ml three times daily)
Number of subjects: 80
Study: 20570659

Group type: EXPERIMENTAL
Intervention: Verbal working memory (digit identity)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Spatial working memory (digit location)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High CE-demand conditions
Number of subjects: 0
Study: 18678800

Group type: EXPERIMENTAL
Intervention: 100 microg of transdermal estradiol
Number of subjects: 102

Group type: COMPARATOR
Intervention: transdermal placebo
Number of subjects: 102
Study: 16448248

Group type: EXPERIMENTAL
Intervention: Maximum Cure (MC) adhesive
Number of subjects: 112

Group type: COMPARATOR
Intervention: Filtek Flow (FF) adhesive
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Maximum Cure (MC) adhesive (maxillary arch)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Filtek Flow (FF) adhesive (maxillary arch)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Maximum Cure (MC) adhesive (mandibular arch)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Filtek Flow (FF) adhesive (mandibular arch)
Number of subjects: 112
Study: 12578931

Group type: EXPERIMENTAL
Intervention: Alzheimer's Disease (AD) patients
Number of subjects: 44

Group type: COMPARATOR
Intervention: Cognitively Normal (CN) subjects
Number of subjects: 44

Group type: COMPARATOR
Intervention: Baseline volume of ERC in CN subjects
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: ERC baseline volumes and annual atrophy rate
Number of subjects: 44
Study: 10368839

Group type: EXPERIMENTAL
Intervention: Knee extensor and flexor muscle training
Number of subjects: 36
Study: 8697293

Group type: EXPERIMENTAL
Intervention: Idazoxan (295 μg/kg)
Number of subjects: 6
Study: 1855093

Group type: EXPERIMENTAL
Intervention: Allogeneic BMT
Number of subjects: 340

Group type: COMPARATOR
Intervention: Autologous BMT
Number of subjects: 340

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 340
Study: 6319151

Group type: EXPERIMENTAL
Intervention: ACTH 1‐17 analogue (100 micrograms i.m.) administered at 7.00 h in winter
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: ACTH 1‐17 analogue (100 micrograms i.m.) administered at 14.00 h in summer
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: ACTH 1‐17 analogue (100 micrograms i.m.) administered at 7.00 h in winter and summer
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: ACTH 1‐17 analogue (100 micrograms i.m.) administered at 21.00 h
Number of subjects: 6
Study: 31256289

Group type: EXPERIMENTAL
Intervention: Trochanteric impaction (TI) with femoral offset (FO) loss
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (no mechanical failure)
Number of subjects: 42
Study: 30252521

Group type: EXPERIMENTAL
Intervention: CRS education plus hands‐on CRS installation training
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: CRS education only
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control (child electricity safety)
Number of subjects: 6
Study: 27166651

Group type: EXPERIMENTAL
Intervention: Sugar, Heart, and Life (SHL) application
Number of subjects: 123
Study: 25321341

Group type: EXPERIMENTAL
Intervention: Bayesian method for electron density mapping
Number of subjects: 8

Group type: COMPARATOR
Intervention: Deformable registration
Number of subjects: 8

Group type: COMPARATOR
Intervention: Intensity approach based on T1
Number of subjects: 8

Group type: COMPARATOR
Intervention: No density correction (set whole head to water)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Bayesian method for bone detection
Number of subjects: 8

Group type: COMPARATOR
Intervention: Deformable registration for bone detection
Number of subjects: 8

Group type: COMPARATOR
Intervention: Intensity approach for bone detection
Number of subjects: 8

Group type: COMPARATOR
Intervention: No density correction for bone detection
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Bayesian method robustness
Number of subjects: 8
Study: 22185621

Group type: EXPERIMENTAL
Intervention: ALC (alcoholic beverage containing 1 g·kg(‐1) body weight)
Number of subjects: 23

Group type: COMPARATOR
Intervention: OJ (nonalcoholic beverage)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: ALC (alcoholic beverage)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: EX OJ (nonalcoholic beverage after eccentric exercise)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: EX ALC (alcoholic beverage after eccentric exercise)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Both treatments (EX OJ and EX ALC)
Number of subjects: 23
Study: 20829420

Group type: EXPERIMENTAL
Intervention: Ultrasound group
Number of subjects: 218

Group type: COMPARATOR
Intervention: Clinical group
Number of subjects: 218
Study: 18510263

Group type: EXPERIMENTAL
Intervention: Quetiapine XR (400-800 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quetiapine XR (300 mg on day 1, 600 mg on day 2, 800 mg on day 3)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quetiapine XR (400-800 mg/day once-daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quetiapine XR
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quetiapine XR (600 mg/day and 800 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16263889

Group type: EXPERIMENTAL
Intervention: Secondary prevention programs with exercise components
Number of subjects: 21295

Group type: EXPERIMENTAL
Intervention: Programs that included risk factor education or counseling with structured exercise
Number of subjects: 21295

Group type: EXPERIMENTAL
Intervention: Programs that included risk factor education or counseling without exercise
Number of subjects: 21295

Group type: EXPERIMENTAL
Intervention: Programs that were solely exercise-based
Number of subjects: 21295
Study: 11943692

Group type: EXPERIMENTAL
Intervention: Moderate intervention group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High intervention group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 9535215

Group type: EXPERIMENTAL
Intervention: Lp(a) serum levels
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: High Lp(a) serum levels
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: High Lp(a) serum levels and IL-6
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Lipid profile
Number of subjects: 75
Study: 7710151

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO) treatment (2.8 ATA for 30 minutes followed by 2.0 ATA oxygen for 90 minutes)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ambient pressure 100% oxygen treatment
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group matched according to age and education level
Number of subjects: 60
Study: 2683715

Group type: EXPERIMENTAL
Intervention: Fructose (20% of calories)
Number of subjects: 21

Group type: COMPARATOR
Intervention: High-amylose cornstarch (20% of calories)
Number of subjects: 21
Study: 197444

Group type: EXPERIMENTAL
Intervention: 30 mg i.m. ACTH4-10
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31524923

Group type: EXPERIMENTAL
Intervention: 1 electronic health record displayed at a time
Number of subjects: 1200

Group type: COMPARATOR
Intervention: 4 electronic health records displayed at a time
Number of subjects: 1200
Study: 29716670

Group type: EXPERIMENTAL
Intervention: Baclofen 30 mg/day
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Baclofen 75 mg/day
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Baclofen (composite groups)
Number of subjects: 104
Study: 27220737

Group type: EXPERIMENTAL
Intervention: Yinchen Zhufu Decoction (YCZFD) and Western medicine (WM)
Number of subjects: 200
Study: 24630935

Group type: EXPERIMENTAL
Intervention: 100%CAPS
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 75%CAPS
Number of subjects: 15
Study: 22341380

Group type: EXPERIMENTAL
Intervention: Inhalation of hypertonic saline before airway clearance techniques
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Inhalation of hypertonic saline during airway clearance techniques
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Inhalation of hypertonic saline after airway clearance techniques
Number of subjects: 50
Study: 21126615

Group type: EXPERIMENTAL
Intervention: Hyperuricemic patients with MS (n = 284)
Number of subjects: 1410

Group type: COMPARATOR
Intervention: Normouricemic patients with MS (n = 1,126)
Number of subjects: 1410

Group type: EXPERIMENTAL
Intervention: Hyperuricemic patients with MS
Number of subjects: 1410
Study: 17438178

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (400 mg 3 times daily)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 16280344

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11918933

Group type: EXPERIMENTAL
Intervention: Simple randomisation
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Urn randomisation
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Mixed randomisation approach
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Permuted-block randomisation
Number of subjects: 200
Study: 10428523

Group type: EXPERIMENTAL
Intervention: Goserelin (subcutaneous depot injections for six months)
Number of subjects: 269

Group type: COMPARATOR
Intervention: Expectant management (surgery only)
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Goserelin
Number of subjects: 269

Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 269
Study: 7473835

Group type: EXPERIMENTAL
Intervention: 30 mg of beta-carotene supplementation for 3 months
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study: 2328310

Group type: COMPARATOR
Intervention: Half-strength formulation (25 mg hydrochlorothiazide and 37.5 mg triamterene)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Full-strength formulation (50 mg hydrochlorothiazide and 75 mg triamterene)
Number of subjects: 0
Study: 7029384

Group type: EXPERIMENTAL
Intervention: Poly chemotherapy
Number of subjects: 133

Group type: COMPARATOR
Intervention: Poly chemotherapy + unspecific immunotherapy with MER
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 133
Study: 31650358

Group type: EXPERIMENTAL
Intervention: Provider estimate
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: 1 week vitamin practice trials
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Self-report (HIV Medication Readiness Scale; Transtheoretical Stages of Change item)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Overall performance of provider estimate
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Mean dose‐taking adherence
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Achievement of optimal adherence
Number of subjects: 176
Study: 31004164

Group type: EXPERIMENTAL
Intervention: Implementation intentions
Number of subjects: 43

Group type: COMPARATOR
Intervention: Rote rehearsal
Number of subjects: 43
Study: 28150044

Group type: EXPERIMENTAL
Intervention: Worst-case scenario (WCS) exercise homework adherence
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Worst-case scenario (WCS) exercise
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Baseline levels of FCR
Number of subjects: 10
Study: 25798568

Group type: EXPERIMENTAL
Intervention: Percutaneous mitral valve repair (pMVR) using the MitraClip system plus optimal medical therapy (OMT)
Number of subjects: 288

Group type: COMPARATOR
Intervention: Optimal medical therapy (OMT) alone
Number of subjects: 288
Study: 23127304

Group type: EXPERIMENTAL
Intervention: Trigger point pressure release therapy (TPPRT)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (no history of PFP)
Number of subjects: 52
Study: 22090049

Group type: EXPERIMENTAL
Intervention: Microsurgical varicocelectomy
Number of subjects: 84

Group type: COMPARATOR
Intervention: Naked eye varicocelectomy
Number of subjects: 84
Study: 19487823

Group type: EXPERIMENTAL
Intervention: Elbow strap orthosis
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Elbow sleeve orthosis
Number of subjects: 52

Group type: COMPARATOR
Intervention: Wrist splint
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo orthosis
Number of subjects: 52